Founded in October 2019 by Prof. Stéphane Depil, MD, PhD, onco-hematologist at CLB, based on the research work from his academic lab, ErVaccine Technologies is a spin off from Centre Léon Bérard (CLB) / Cancer Research Center of Lyon (CRCL).
Currently at a preclinical stage of development, the company specializes in the development of next generation cancer vaccines, and cell therapies based on modified T lymphocytes, targeting new families of non-conventional tumor antigens such as those derived from endogenous retroviruses (identified and patented therapeutic targets).
Know more